Sarah C. Bening

Sarah C. Bening

Auto-generated profile, based on publicly available information

Sarah C. Bening

Institute for Medical Engineering & Science, Department of Biological Engineering, and Synthetic Biology Center, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Science
Verified
Journal Article
Closed access
PDF file
ALAllison J. Lopatkin
Allison J. Lopatkin
SBSarah C. Bening
Sarah C. Bening
AMAbigail L. Manson
Abigail L. Manson
JSJonathan M. Stokes
Jonathan M. Stokes
MKMichael A. Kohanski
Michael A. Kohanski
JCJames J. Collins
James J. Collins
Although metabolism plays an active role in antibiotic lethality, antibiotic resistance is generally associated with drug target modification, enzymatic inactivation, and/or transport rather than metabolic processes. Evolution experiments of Escherichia coli rely on growth-dependent selection, which may provide a limited view of the antibiotic resistance landscape. We sequenced and analyzed E. coli adapted to representative antibiotics at increasingly heightened metabolic states. This revealed various underappreciated noncanonical genes, such as those related to central carbon and energy metabolism, which are implicated in antibiotic resistance. These metabolic alterations lead to lower basal respiration, which prevents antibiotic-mediated induction of tricarboxylic acid cycle activity, thus avoiding metabolic toxicity and minimizing drug lethality. Several of the identified metabolism-specific mutations are overrepresented in the genomes of >3500 clinical E. coli pathogens, indicating clinical relevance.

5 January 2022 in Cell Chemical Biology
Verified
Journal Article
Open access
MLMichael A. Lobritz
Michael A. Lobritz
IAIan W. Andrews
Ian W. Andrews
DBDana Braff
Dana Braff
CPCaroline B.M. Porter
Caroline B.M. Porter
AGArnaud Gutierrez
Arnaud Gutierrez
JCJames J. Collins
James J. Collins
β-lactam antibiotics disrupt the assembly of peptidoglycan (PG) within the bacterial cell wall by inhibiting the enzymatic activity of penicillin-binding proteins (PBPs). It was recently shown that β-lactam treatment initializes a futile cycle of PG synthesis and degradation, highlighting major gaps in our understanding of the lethal effects of PBP inhibition by β-lactam antibiotics. Here, we assess the downstream metabolic consequences of treatment of E. coli with the β-lactam mecillinam and show that lethality from PBP2 inhibition is a specific consequence of toxic metabolic shifts induced by energy demand from multiple catabolic and anabolic processes, including accelerated protein synthesis downstream of PG futile cycling. Resource allocation into these processes is co-incident with alterations in ATP synthesis and utilization, as well as a broadly dysregulated cellular redox environment. These results indicate that the disruption of normal anabolic-catabolic homeostasis by PBP inhibition is an essential factor for β-lactam antibiotic lethality.